A Randomized, Crossover Study Assessing the Effect of EFB0027 on Plasma Glucose and Pharmacokinetics in Subjects With Type 2 Diabetes Mellitus

Trial Profile

A Randomized, Crossover Study Assessing the Effect of EFB0027 on Plasma Glucose and Pharmacokinetics in Subjects With Type 2 Diabetes Mellitus

Completed
Phase of Trial: Phase I/II

Latest Information Update: 17 Oct 2016

At a glance

  • Drugs Metformin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacokinetics; Therapeutic Use
  • Sponsors Elcelyx Therapeutics
  • Most Recent Events

    • 21 Aug 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 09 Mar 2013 New trial record
    • 14 Feb 2013 Primary endpoint 'Improved glucose level' has been met, according to an Elcelyx media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top